AMGN
Amgen Inc.
AMGN has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AMGN overall, supported by stronger valuation and stronger fundamentals.
AMGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Stable |
AMGN's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $319 | -32% |
| Forward | 19x | $467 | — |
| Fair | 22x | $381 | -18% |
| Expensive | 27x | $465 | -0.5% |
| Current | 27x | $467 | — |
Historical ranges are pointers, not guarantees.
AMGN's PE is in its expensive range at 27x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AMGN in the historical PE scenario, which offers more potential upside but is not a forecast.
AMGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for AMGN, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AMGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.33 | +41% |
| Q3 2026 | $17.24 | +33% |
| Q2 2026 | $16.09 | +31% |
| Q1 2026 | $14.37 | +31% |
| Q4 2025 | $14.23 | +88% |
| Q3 2025 | $12.95 | +66% |
| Q2 2025 | $12.24 | +111% |
| Q1 2025 | $10.97 | +57% |
| Q4 2024 | $7.56 | -39% |
AMGN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AMGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.4B | +8.5% |
| Q2 2026 | $10.1B | +9.5% |
| Q1 2026 | $8.6B | +5.8% |
| Q4 2025 | $9.9B | +8.6% |
| Q3 2025 | $9.6B | +12% |
| Q2 2025 | $9.2B | +9.4% |
| Q1 2025 | $8.1B | +9.4% |
| Q4 2024 | $9.1B | +11% |
AMGN's revenue has grown year over year for 14 quarters in a row: $10.4B last quarter, up 8.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +9.4 points |
| Q2 2026 | 35% | +6 points |
| Q1 2026 | 31% | +17 points |
| Q4 2025 | 28% | +2.1 points |
| Q3 2025 | 26% | +2.4 points |
| Q2 2025 | 29% | +6.2 points |
| Q1 2025 | 14% | +1.2 points |
| Q4 2024 | 25% | +9.9 points |
AMGN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMGN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AMGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | -14% |
| Q2 2026 | $3.5B | +83% |
| Q1 2026 | $1.5B | +51% |
| Q4 2025 | $961M | -78% |
| Q3 2025 | $4.2B | +28% |
| Q2 2025 | $1.9B | -14% |
| Q1 2025 | $980M | +114% |
| Q4 2024 | $4.4B | +1422% |
AMGN's free cash flow has been positive every quarter for seven years: $9.6B over the past year, down 17% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AMGN on cash flow, with more consistent year-over-year improvement.
AMGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +2M shares |
| 1 year | +0.7% | +4M shares |
| 3 years | +1.5% | +8M shares |
| 5 years | -4.2% | -24M shares |
| Available history | -10% | -63M shares |
AMGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | $6.4B |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 3.8x | Elevated |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 3.7x | Elevated |
| Q4 2024 | 3.8x | Elevated |
AMGN's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.8 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AMGN on leverage, with a lower net debt burden relative to earnings.
AMGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.2 | Neutral |
| Stochastic | 84.5 | Overbought |
AMGN's weekly RSI is 67 (neutral) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMGN PE vs Healthcare Sector
| Metric | AMGN | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 4.8% above |
| PE % | 84 | 29 | 55 pts above |
AMGN is trading at 27x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AMGN on valuation relative to its sector.
AMGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $437.2 | 6.8% above |
| 20 week MA | $413.1 | 13% above |
| 50 week MA | $373.0 | 25% above |
| 100 week MA | $332.6 | 40% above |
| 200 week MA | $304.8 | 53% above |
AMGN is in an uptrend: it's above all five of its weekly moving averages, and 53% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
AMGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $241.5 | $222.9 | -7.7% |
| 2021 | $222.9 | $223.8 | +0.4% |
| 2022 | $223.8 | $263.9 | +18% |
| 2023 | $263.9 | $288.0 | +9.1% |
| 2024 | $288.0 | $262.7 | -8.8% |
| 2025 | $262.7 | $332.9 | +27% |
| 2026 YTD | $332.9 | $467.1 | +40% |
AMGN has finished higher in four of the last six years. It's up 40% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AMGN on returns for 2026, with the stronger performance.